We are delighted to welcome you to the European Association for the Study of the Liver (EASL) and the Turkish Association for the Study of the Liver (TASL) Digital Hepatology Meeting “Clinical Innovations and Controversies in ILC 2021” on October 16, 2021. EASL and TASL have been collaborated to organize educational activities for a long time. We have brought together a series of excellent lectures delivered by a renowned national and international faculty. The program promises high-class educational opportunities for all who are interested in clinical practice and research in hepatology.
The program of this educational activity consist of 4 sessions spanning a whole day. They include Metabolic Liver Diseases, Viral Hepatitis, HCC, and Cirrhosis and Liver Transplantation. To bring out the clinical relevance of the material covered, each session will incorporate case-based discussion by a panel of faculty experts with interactive participation of the audience.
Target audience is gastroenterologist, hepatologists, trainees, infectious disease specialists, emergency physicians, primary care physicians with interest in hepatology, translational and clinical researchers and other health care professionals.
Highlights:
BEST OF EASL ILC at TASL - Clinical innovations and Controversies
16 October 2021
9:20-9:30 Welcome and Opening Ceremony
9:30-11.00 Metabolic Liver Diseases: NAFLD/ALD
Moderators: Nurdan Tözün, Elisabetta Bugianesi
09.30-09.45 Strategies for assessing liver disease severity and prognosis in NAFLD: Jerome Boursier, France
09.45-10.00 Linking histopathology features with disease mechanisms in ALD: Caroline Lackner, Austria
10.00-10.15 New data from ILC 2021: Massimo Pinzani, UK
10.15-11.00 Case presentation and Panel discussion - clinical innovations and controversies
Presenter: Arif Mansur Coşar
Panelists: Fulya Günşar, Yusuf Yılmaz, Müjdat Zeybel, Emmanuel Tsochatzis, Caroline Lackner, Massimo Pinzani
11.00-11.15 BREAK
11.15-12.45 Cirrhosis and Liver Transplantation
Moderators: Thomas Berg, Zeki Karasu,
11.15-11.30 Liver transplantation in patients with ACLF: Thierry Gustot, Belgium
11.30-11.45 Old drugs for novel treatment strategies in cirrhosis: Elisa Pose, Spain
11.45-12.00 New data from ILC 2021: Didier Samuel, France
12.00-12.45 Case presentation and Panel Discussion - clinical innovations and controversies
Presenter: Gözde Derviş Hakim
Panelists: Yaman Tokat, Meral Akdoğan, Murat Akyıldız, Elisa Pose, Didier Samuel
12.45-13.30 LUNCH BREAK
13.30-15.00 Viral Hepatitis
Moderators: Maria Buti, Cihan Yurdaydın
13.30-13.45 WHO new guidance on Viral Hepatitis elimination: Philippa Easterbrook, Switzerland
13.45-14.00 HBsAg and serum RNAs as markers to detect and quantify HBV integrates: Ivana Carey UK
14.00-14.15 New data from ILC 2021: Anna Lok, US
14.15-15.00 Case presentation and Panel discussion - clinical innovations and controversies
Presenter: Remzi Akdoğan
Panelists: Halis Şimşek, Suna Yapalı, Bülent Değertekin, Philippa Easterbrook, Ivana Carey, Anna Lok
15.00-15.15 BREAK
15.15-16.45 HCC
Moderators: Maria Reig, Sabahattin Kaymakoğlu,
15.15-15.30 How are the new phase III data changing the treatment landscape of unresectable HCC?: Lorenza Rimassa, Italy
15:30-15:45 Immunotherapy in HCC: Bruno Sangro, Spain
15.45-16.00 New data from ILC 2021: Josep Llovet, US
16.00-16.45 Case presentation and Panel Discussion – clinical innovations and controversies
Presenter: Diğdem Özer Etik
Panelists: Ulus S Akarca, Ömer Özbakır, Levent Doğanay, Lorenza Rimassa, Josep Llovet, Alejandro Forner
